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Attention is increasingly being focussed on probiotics as potential agents to restore or
improve gastrointestinal (GI) transit. Determining mechanism of action would support
robust health claims. The probiotic bacterium Bifidobacterium lactis HN019 reduces
transit time, but its mechanisms of action and effects on motility patterns are poorly
understood. The aim of this study was to investigate changes in GI motility induced by
an extract of HN019 on distinct patterns of colonic motility in isolated rat large intestine,
compared with a known promotility modulator, prucalopride. The large intestines from
male Sprague Dawley rats (3–6 months) were perfused with Kreb’s buffer at 37◦C in
an oxygenated tissue bath. Isometric force transducers recorded changes in circular
muscle activity at four independent locations assessing contractile propagation between
the proximal colon and the rectum. HN019 extract was perfused through the tissue bath
and differences in tension and frequency quantified relative to pre-treatment controls.
Prucalopride (1 µM) increased the frequency of propagating contractions (by 75 ± 26%)
in the majority of preparations studied (10/12), concurrently decreasing the frequency of
non-propagating contractions (by 50± 11%). HN019 extract had no effect on contractile
activity during exposure (n = 8). However, following wash out, contraction amplitude of
propagating contractions increased (by 55± 18%) in the distal colon, while the frequency
of non-propagating proximal contractions decreased by 57 ± 7%. The prokinetic action
of prucalopride increased the frequency of synchronous contractions along the length of
colon, likely explaining increased colonic rate of transit in vivo. HN019 extract modified
motility patterns in a different manner by promoting propagating contractile amplitude
and inhibiting non-propagations, also demonstrating prokinetic activity consistent with
the reduction of constipation by B. lactis HN019 in humans.
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INTRODUCTION
Constipation is a common functional gastrointestinal (GI)
disorder affecting 20% of the general population worldwide
(Vazquez Roque and Bouras, 2015). As a frequently subclinical
undiagnosed condition, preventative therapeutic strategies and
treatments using natural products are often sought in preference
to pharmaceuticals. Probiotic bacteria are attributed with health
promoting properties for improving GI discomfort and there
are a growing number of studies supporting alteration of GI
motility patterns (Ohashi et al., 2001; Lesniewska et al., 2006;
Massi et al., 2006; Wang et al., 2010a,b; Wu et al., 2013; Dalziel
et al., 2015).
Beneficial probiotic bacteria have been shown to improve
symptoms of GI discomfort through relief of constipation and/or
diarrhea in clinical studies (Ringel et al., 2012; Sanders et al.,
2013). A meta-analysis of randomized controlled trials found
that short-term probiotic supplementation decreases GI transit
time in constipated or older adults (Miller and Ouwehand,
2013). For example, Lactobacillus casei Shirota has been shown
to reduce colonic transit time in female adults, relieving
chronic constipation (Krammer et al., 2011), and to reduce
antibiotic associated diarrhea (Wong et al., 2014). The probiotic
Bifidobacterium lactis HN019 reduces total transit time in adults
with functional GI constipation when used alone (Waller et al.,
2011) or in combination with other probiotic strains (Magro
et al., 2014), and decreases the severity of diarrhea in piglets
(Shu et al., 2001). Some of these effects may occur indirectly, for
example B. lactis HN019 supplementation increases the resident
bifidobacteria population in feces (Ahmed et al., 2007) and these
species are reduced in functional constipation in the elderly (Kim
et al., 2015). However, it is unknown whether B. lactis HN019
might also act directly on enteric neurons in the large intestine
to alter motility patterns and thus influence GI transit of solid
contents.
The propulsion of luminal contents is coordinated by
synchronized contraction and relaxation of GI smooth muscles
that are largely controlled by the enteric nervous system (Spencer
et al., 2016). Although serotonin is present at high levels
in GI tissue, serotonin neurotransmission is not required for
the major colonic motor patterns associated with orderly GI
transit (Spencer, 2015). Rather, serotonin receptors located
on enteric neurons (intrinsic primary afferent neurons in the
submucosal plexus) have a modulatory role in coordinating
contractile function and are therefore the target of therapeutic
treatments for colonic dysmotility, particularly constipation. The
serotonin agonist prucalopride is highly selective for the 5-HT4
receptor subtype and is used to treat severe constipation due to
decreased GI motility, by stimulating colonic mass movements
which provide the main propulsive force for defecation (Bouras
et al., 1999). Prucalopride is known to increase the frequency
of colonic contractions in the isolated rat large intestine (Yu
et al., 2015) and we have recently shown that prucalopride
increases colonic transit of solids in vivo (Dalziel et al., 2016).
As a promotility modulator with a specific mode of action,
prucalopride is considered a benchmark compound to compare
against substances with an unknown mechanism of action.
The aim of this research was to characterize and quantify
changes in GI motility patterns underlying propulsion of luminal
contents due to the probiotic bacterium B. lactis HN019, which
is known to reduce constipation in humans (Waller et al., 2011).
We hypothesized that the reduced constipation effect of HN019
is attributed to enhanced synchronous contractions in the colon.
We used an ex vivo rat model of colonic motility because this
provides a well-accepted model for human GI motility studies
(Dalziel et al., 2014, 2015) and motility patterns that propel
contents are well described for this species (Chen et al., 2013;
Costa et al., 2013). We compared the effect of HN019 on motility
patterns with that of prucalopride.
We have found bacterial extracts (Dalziel et al., 2015) to be
effective at altering motility in this model, as have other in vitro
studies using bacterial extract from different sources (Massi et al.,
2006; Bar et al., 2009). We examined the effect of prucalopride
and B. lactis HN019 on contractile amplitude and frequency of
spontaneous muscle contractions in the isolated rat colon. The
pattern of contractions was studied by comparing the probability
that a contraction occurring in the proximal colon would fully
propagate through to the mid-colon, distal colon and rectum and
therefore be synchronized in time.
METHODS
Bacterial Extract
A bacterial extract was used in this study as opposed to live
bacteria because B. lactis HN019 is a facultative anaerobe so
would not be compatible with the oxygenated tissue bath used
here. While HN109 may survive in the aerobic assay conditions,
its metabolism would be greatly altered compared to what
would occur in the colon. Facultative anaerobes switch between
fermentation and anaerobic respiration depending on whether
oxygen is present or not, which results in the production of
different sets of metabolites. In contrast to the assay conditions,
the human colonic lumen is almost oxygen-free (O2 partial
pressure < 1mM Hg) (Espey, 2013). Therefore in this study
we chose to grow HN019 in anaerobic conditions so that it
would produce the metabolite profile expected in the colon, and
then add this anaerobic produced extract to the assay. B. lactis
HN019 stock cultures were supplied by Fonterra Research &
Development Centre. HN019 primary culture was inoculated
from a secondary plate into 10 mL of MRS broth (Merck) and
incubated at 37◦C in an anaerobic workstation (Concept Plus,
Ruskin Technology Ltd, UK) containing 10% CO2, 10% H2 and
80% N2 for 48 h. A 50 mL secondary culture was inoculated
with 0.5 mL of primary broth (adjusted to an OD600 of 1.5) and
incubated anaerobically for 16 h. Two 150 mL secondary cultures
were inoculated with 1.5mL of secondary broth and incubated
anaerobically for 16 h to the stationary phase. The bacterial
cell culture was harvested and processed into extract under
anaerobic conditions, then used in themotility assays freshly each
day. Bacterial cells were collected by centrifugation (10,845 g for
20 min at 4◦C) and resuspended in 5 mL of anaerobic Krebs
solution (118mM NaCl, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM
MgSO4, 2.6mM CaCl2, 25mM NaHCO3, 11mM glucose, pH
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7.4). The bacterial cell pellet was washed twice in Krebs solution,
resuspended in 5mL and incubated on ice for 10 min. The
mixture was then sonicated on ice using 20 s pulses with 30 s
intervals, power level 2 at 40% duty for 10 min (Vibra-Cell,
Sonics and Materials, Newtown, USA). The sonicated mixture
was then centrifuged (10,845 g for 30 min) to remove the cell
debris and the resulting supernatant was ultra-centrifuged to
remove any remaining cell membranes (300,000 g for 2 h) and
to prevent excessive frothing of the solution in the motility
experiment phase. The final supernatant was a cell-free extract
(HN019 extract) that was adjusted to pH 7.4 (with 5 M sodium
hydroxide) and diluted 1/10 dilution in Kreb’s solution for use in
the motility assay.
Animals
This study was carried out in strict accordance with the
recommendations of the New Zealand Animal Welfare Act
1999. The protocol was approved by the AgResearch Limited
(Grasslands) Animal Ethics Committee (Ethics Approval No.:
AE13449). Male adult Sprague Dawley rats, 3–6 months of age,
weighing 250–400 g were obtained from AgResearch Ruakura
(Hamilton, NZ). The rats were housed under a 12 h light/dark
cycle, and fed Sharpes Diet 86 (Sharpes Stockfeeds Ltd.,
Carterton, New Zealand). Food and water were available ad
libitum.
Whole Large Intestine
The protocol for recording motility in isolated intact whole
large intestine has recently been described (Dalziel et al., 2014,
2015). Briefly, following initial isoflurane anesthesia using a drop-
box, the animal was maintained on 5% isoflurane via nose cone
and placed in dorsal recumbency. A midline laparotomy was
performed and the entire large intestine removed and placed
immediately in a beaker containing oxygenated Krebs solution
to preserve enteric neuron function. The animal then received an
intra-cardiac injection of a lethal dose of sodium pentobarbital.
The beaker containing the tissue received further carbogen gas
(95% O2, 5% CO2) whilst the colon was gently flushed with
Krebs solution to expel fecal pellets and the entire tissue was
thenmounted in an organ bath (approximately 350mL capacity),
a stainless steel rod (35 cm in length and 2mm in diameter)
was inserted through the lumen of the colon, which was then
perfused at 20 mL/min with Krebs buffer at 35 ± 1◦C. The
lumen was also perfused with Krebs buffer at 1.5 mL/min which
was pumped aborally using a constant flow pump because this
provided the pressure required to record consistent propagating
contractions. Changes in circular muscle tension were recorded
from four sites simultaneously along the length of large intestine,
using four custom-made metal hooks anchored 3 cm from both
oral and anal ends of the preparation and evenly spaced apart at
approximately 4 cm intervals. These hooks were connected via
silk thread to force transducers and contractions measured after
applying 2 g of tension. Muscle contraction data were recorded
using isometric force transducers (MLT0201) connected to an
eight-channel bridge amplifier, integrated using PowerLab 8/35
hardware and acquired and analyzed using LabChart 8 software.
All recording equipment hardware and software were from
ADInstruments Pty Ltd., Bella Vista, NSW, Australia.
Definition Criteria for Motility
Patterns—Synchronous vs.
Non-synchronous
“Synchronous contractions” were defined as contractions that
were temporally coordinated and occurring at four independent
isometric recording sites. It is recognized that their precise
direction of propagation cannot be quantified based on the
resolution of four recording sites alone (Spencer et al., 2016).
This definition would therefore, in theory, include contractions
that propagated in either an anterograde (anally migrating),
retrograde (orally migrating), or bi-directionally propagating
(i.e., starting in the mid colon and propagating both in
an anterograde and retrograde direction). Non-synchronous
contractions were those occurring in the proximal colon that
were not temporally coordinated withmore distal recording sites.
Contraction frequency and amplitude were measured during
a 30 min control recording and compared with that over 0–30
and 30–60 min of exposure to treatments, and following 60 min
of washout. Because these synchronous and non-synchronous
contractions are likely play a major role for coordinated
propulsion of luminal contents, they were statistically compared
between pre-treatment control and treatment groups. All
pharmacological agents and HN019 extract were applied to the
serosal side of each preparation, via the perfusion tube supplying
the bath. Thus, these substances would need to be absorbed
and reach the peripheral circulation to be capable of modulating
colonic motility.
Statistical Analysis
Results are expressed as the mean ± SEM from 8 to 10 animals.
Repeated measures analysis of variance (ANOVA) with one
experimental factor (the three treatments) and one repeated
factor (four time points) was used to analyze differences in the
frequency and amplitude of synchronous contractions within
experiments, and also compared with the Krebs treatment
control. All analyses were carried out using the R software version
3.2.3. ANOVA assumptions were met through log or square root
transformation where necessary. Linear mixed effects models
were used with appropriate variance function for modeling
heterodasticity.
Data were excluded from statistical analysis where they were
contrary to the main effects observed: 2/12 preparations for
prucalopride and 2/10 preparations for HN019, and are described
in the results section.
RESULTS
Contractile patterns were recorded from the circular muscle
layer at four locations simultaneously along the length of the
large intestine (proximal colon, mid-colon, distal colon, and
rectum), before and after addition of treatment conditions.
Motility patterns were quantified with respect to changes in
frequency and amplitude of synchronous and non-synchronous
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phasic contractions, and contractions that occurred only in the
proximal colon (Figure 1).
Krebs Treatment Control Did Not Alter
Synchronous Contraction Patterns
An initial control experiment was carried out using Krebs
buffer to provide a treatment condition, with the aim to
ascertain whether any time-dependent changes in contractility
occurred and for statistical comparison among treatment groups
(Figure 1A). During the 30 min pre-treatment recording,
following exposure to Krebs buffer for 1–2 h, 4.4 ± 0.4
(mean ± SEM; n = 8) synchronous contractions occurred
between proximal colon and rectum. Although no changes
in synchronous contractions were detected over the course of
the experiment (Figure 2), the frequency of non-synchronous
contractions decreased by 15 ± 8% and the peak force generated
during non-synchronous contractions increased by 21 ± 10%,
over 30–60 min (Figure 3).
Prucalopride Increased the Frequency of
Propagating Synchronous Contractions
Application of 1 µM prucalopride to the large intestine tissue
increased motility (Figure 1B) by increasing the frequency
of propagating synchronous contractions compared with the
control; by 58 ± 19% (n = 10) over the initial 30 min of
exposure and by 75 ± 26% over 30–60 min exposure. This
occurred without any change in amplitude (Figures 2A,B, 4A).
The increased effects of prucalopride on contractility persisted
for extended periods of time (at least 30 min following washout).
Concomitantly, prucalopride decreased the frequency of non-
synchronous contractions that occurred in the proximal colon
(by 50 ± 11% after 60 min, Figure 3A). Contractile amplitude
was 62% less than the Krebs treatment control at 60 min
(Figure 3B). These effects also persisted following wash out
of prucalopride. In 2/12 preparations prucalopride inhibited
synchronous contractions by 50% (these preparations only
returned to 30% of pre-treatment frequency after wash out) yet
tension was increased by 20–36% across the four recording sites
from the mid-colon to the rectum.
HN019 Extract Increased Contractile
Amplitude after Washout
Application of HN019 extract (10%) to the large intestine resulted
in no detectable change in contractile activity over 60 min, yet
it was found that within the first 30 min following washout of
HN019, the contractile amplitude increased by 55 ± 18% in
the proximal colon (Figures 1C, 2A,B). Post-exposure, HN019
extract increased the amplitude of synchronous contractions
along the length of the large intestine, particularly in the
distal colon (Figure 4B). In 2/10 experiments HN019 extract
completely inhibited synchronous contractions during 60 min
of exposure and these returned to pre-treatment levels following
wash out.
HN019 extract decreased the amplitude of non-synchronous
contractions in the proximal colon to 30% lower than that for the
corresponding Krebs treatment control at 60min (Figure 3B).
The inhibitory effect of HN019 extract on non-synchronous
contractility persisted following wash out of the treatment, with
a 33% decrease in frequency and a 38% decrease in contractile
amplitude compared with the Krebs treatment control.
Ratio of Non-synchronous to Synchronous
Contractions
The ratio of non-synchronous to synchronous contractions
averaged 5.2:1 across the pre-treatment controls (for Krebs,
prucalopride, and HN019 extract) and was reduced to 1.0:1
after 60 min of prucalopride, and 1.6:1 for HN019 extract post-
treatment, yet remained high at 5.0:1 for the Krebs control
(Figure 5).
DISCUSSION
The main findings of this study are that the predominant
effect of HN019 extract was to markedly increase contractile
amplitude of synchronous contractions spanning the proximal
colon to the rectum, and that this effect occurred post-treatment.
This supports our hypothesis that the reduced constipation
effect of HN019 can be attributed to enhanced synchronous
contractions in the colon. In contrast, the known prokinetic,
prucalopride altered colonic motility patterns of spontaneous
phasic contractions by increasing the frequency of synchronous
contractions in the rat isolated large intestine both during and
after treatment. The delayed effect of HN019 was unexpected
and differed from prucalopride in that contractile amplitude was
affected rather than frequency suggesting a different mechanism
of action. Both prucalopride and HN019 extract demonstrated
a secondary action in decreasing the proportion of non-
synchronized to synchronized contractions. These findings may
provide important insights for human patients that report altered
large intestine motility habits upon consumption of these agents.
The synchronous contractions recorded were similar to those
reported previously using this method (Costa et al., 2013; Dalziel
et al., 2014, 2015). The continuity of motility parameters over
the duration of the Krebs treatment control experiment provided
a stable comparison with treatment experiments. Although a
time-dependent decrease in the frequency of non-synchronous
contractions was detected with Krebs treatment, this was
markedly less than the main treatment effects for prucalopride
and HN019 extract.
Prucalopride
In the presence of prucalopride there was an increase in the
proportion of contractions in the proximal colon that became
synchronous along the length of the large intestine. Concurrently,
there was a decrease in the frequency of isolated contractions
in the proximal colon. This finding is consistent with its action
as a promotility modulator in the colon and supports its anti-
constipation effects in vivo (Bouras et al., 1999).
Our finding that prucalopride increased the frequency
of synchronous contractions would be consistent with a
coordinated firing of enteric neurons in the enteric nervous
system (Yu et al., 2015). The concurrent decrease in the
frequency of non-propagating contractions was surprising and
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FIGURE 1 | Contractile motility patterns in the isolated large intestine. Representative examples show a 10 min recording of muscle contraction from each of
the four recording locations for the pre-treatment control (after 1–2 h of equilibration), over 30–60 min of treatment with: (A) Krebs buffer treatment control, (B) 1 µM
prucalopride, and (C) HN019 extract (10%), and following 60 min of washout with Krebs buffer. The enlarged windows show synchronous contractions that overlap in
time.
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FIGURE 2 | Summary graphs of treatment effects on synchronous
motility parameters in the isolated large intestine. Data are shown as
percent change from the pre-treatment control for: Krebs buffer treatment
control (black) (n = 8), prucalopride (dark gray) (n = 10), and HN019 extract
(10%) (light gray) (n = 8). Synchronous contractions between the proximal
colon and the rectum that were temporally coordinated in anterograde, mid, or
retrograde direction were measured during a 30 min control recording and
compared with that over 0–30 and 30–60 min of exposure to treatments, and
following 60 min of washout. Contraction (A) frequency and (B) amplitude
(Continued)
FIGURE 2 | Continued
are shown for the proximal colon. (C) The amplitude of synchronous
contractions are shown as percent change in contractile amplitude from the
pre-treatment control at all four locations (T1, proximal; T2, mid; T3, distal; T4,
rectal) for Krebs buffer control treatment condition (n = 8), and following 60
min of washout with Krebs buffer. Statistical significance was determined using
repeated measures ANOVA and treatment compared with either Krebs buffer
treatment control or the pre-treatment control. Asterisks indicate statistical
significance (*p < 0.05; ***p < 0.001). Data show mean ± SEM.
the mechanisms responsible are unclear. Altered motility
patterns in which their generation is dependent upon enteric
ganglia have been reported for prucalopride using spatiotemporal
mapping in which mid- and distal colon contractions are
increased yet full length synchronous contractions are decreased
in both length and frequency (Yu et al., 2015). While our method
does not have the resolution to directly compare frequency with
this previous study, we note a common effect of prucalopride
increasing coordinated distal colon contractions.
5-HT4 receptors are expressed throughout the GI tract on
numerous cell types, such as enterochromaffin cells and intrinsic
primary afferent neurons, including different functional types
of myenteric neurons and smooth muscle cells (De Maeyer
et al., 2008). Prucalopride could therefore act at multiple
sites to modulate regional and/or time-coordinated relaxation-
contractionmechanisms of GImotility patterns (DeMaeyer et al.,
2008). Although 5-HT4 receptors are predominately expressed
in the rat myenteric ganglia neurons, they are also expressed
at low levels in colonic circular muscle and very low levels in
longitudinal muscle and in the interstitial cells of Cajal (Poole
et al., 2006). Therefore, a direct effect of prucalopride on 5-HT4
receptors in isolated colonic preparations is clearly a possibility.
Because the 5-HT4 receptor is a G-protein coupled receptor,
agonist binding leads to protein kinase A activation resulting
in a prolonged excitatory response (Costedio et al., 2007). In
the case of myenteric cholinergic excitatory neurons, this leads
to increased acetylcholine release and increased contraction
(De Maeyer et al., 2008). However, the inhibitory effect of
prucalopride on non-synchronous contractions in the proximal
colon was slow in onset and long-lasting, suggesting a secondary
effect on cellular signaling. The decrease in frequency in the
Krebs treatment control suggests that prucalopride may have
accelerated a time-dependent process. Another potential reason
for variation in the effect of prucalopride on motility is that it
is more potent on the 5-HT4b splice variant than the 5-HT4a
(Pindon et al., 2002). How such an effect would alter motility
patterns is unclear.
B. lactis HN019
The enhanced motility effects demonstrated for HN019 extract
suggest involvement by the enteric neural circuitry responsible
for propulsive neurogenic colonic patterns by increasing the
amplitude of propagating contractions in the colon. Further
study is required to corroborate this finding and determine
the underlying mechanisms involved. Thus, HN019, a probiotic
known to reduce constipation increased the strength of colonic
Frontiers in Neuroscience | www.frontiersin.org 6 January 2017 | Volume 11 | Article 20
Dalziel et al. Motility Changes Induced by B. lactis
FIGURE 3 | Summary graphs of treatment effects on non-synchronous
motility parameters in the isolated large intestine. Data are shown as
percent change from the pre-treatment control for: Krebs buffer treatment
control (black) (n = 8), prucalopride (dark gray) (n = 10), and HN019 extract
(10%) (light gray) (n = 8). Non-synchronous contraction (A) frequency and (B)
amplitude, were measured during a 30 min control recording and compared
with that over 0–30 and 30–60 min of exposure to treatments, and following
60 min of washout. Amplitude was measured in the proximal colon. Statistical
significance was determined using repeated measures ANOVA and treatment
compared with either Krebs buffer treatment control or the pre-treatment
control (a shown only for Krebs). Asterisks indicate statistical significance (*p <
0.05; **p < 0.01; ***p < 0.001). Data show mean ± SEM.
contractions in the isolated large intestine ex vivo. Our finding
that HN019 extract also decreased non-propagating contractions
suggests at least two separate effects.
The post-treatment effect of HN019 extract at increasing the
strength of colonic contractions showed a considerable delay.
The mechanism underlying this response is not clear and may
be a consequence of removal of the extract rather than a gradual
excitatory effect over time. Given that HN019 extract is a mixture
of components, multiple actions would be anticipated.
The inhibitory effect of HN019 extract on non-synchronized
contractions in the proximal colon was similar to that for
prucalopride. Synchronous contractions that propagate along
the length almost certainly require enteric neural activity and,
consistent with this idea, are abolished by nerve conduction
FIGURE 4 | Summary graphs of treatment effects on amplitude of
synchronous contractions in the isolated large intestine. Data are
shown as percent change in contractile amplitude from the pre-treatment
control at all four locations (T1, proximal; T2, mid; T3, distal; T4, rectal) for
treatment conditions of: (A) 1 µM prucalopride (n = 10), and (B) HN019
extract (10%) (n = 8), and following 60 min of washout with Krebs buffer.
Statistical significance was determined using repeated measures ANOVA and
treatments compared with Krebs buffer treatment control (shown in
Figure 2C). Data show mean ± SEM. Asterisks indicate the significance of
each treatment relative to controls (*p < 0.05; **p < 0.01; ***p < 0.001).
blockers (Costa et al., 2013; Dalziel et al., 2014), while those
that do not propagate large distances are often of non-neural
origin (Dalziel et al., 2014) in this preparation. These non-
propagating contractions are generated by the interstitial cells
of Cajal (ICC) (Huizinga et al., 2014). Thus, it is tempting
to speculate that HN019 extract and prucalopride have a
similar mechanism of action to decrease the frequency of non-
propagating contractions. Experiments using tetrodotoxon to
silence enteric neurons would demonstrate whether HN019
extract affects the musculature or the ICC directly.
Given that our study was ex vivo using serosal application of
bacterial extract, the results assume that the bacterial secreted
products would be absorbed and reach the peripheral circulation
to be active at modulating colonic motility.
A previous study showed that HN019 given as live bacteria
is effective at reducing total transit time in slightly constipated
subjects (stool type of 2–4 on the Bristol Stool Chart and 1–
3 bowel movements per week) (Waller et al., 2011). Our study
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FIGURE 5 | Comparison of contractile frequency for synchronous
(black) and non-synchronous (gray) contractions measured in the
proximal colon. Data are shown as number of contractions per minute for
pre-treatment, treatment condition of: (A) Krebs buffer treatment control (n =
8), (B) 1 µM prucalopride (n = 10), or (C) HN019 extract (10%) (n = 8), and
following 60 min of washout with Krebs buffer. Statistical significance was
determined using repeated measures ANOVA and treatments compared with
the Krebs buffer treatment control. Data show mean ± SEM. Asterisks indicate
the significance of each treatment relative to controls (*p < 0.05; **p < 0.01;
***p < 0.001).
reveals that lysed HN019 contents are sufficient to modify
contractile patterns in the colon that fit a pro-motility profile
of increased contractile amplitude. The mechanism by which
this occurs is unclear. The ability to improve the synchrony
of contractions by decreasing dysmotility might explain why
HN019 is also able to reduce the severity of weanling diarrhea
associated with rotavirus and E. coli in a piglet model over
the first 3 days post-weaning (Shu et al., 2001). A related
strain (GCL2505) of the Bifidobacterium lactis species has
recently been reported to slightly increase fecal output in a
rat model of constipation induced by loperamide (Aoki et al.,
2016).
CONCLUSION
This study supports a known prokinetic action for prucalopride
that was demonstrated by an increased frequency of
synchronized contractions in the proximal colon. This result
could explain the known increase in colonic transit induced
by prucalopride, often reported as increased emptying in the
proximal colon. The change in the contractile patterns we
report for prucalopride provides a benchmark for improved
colonic transit against which the probiotic HN019 extract was
compared.
A major finding of this study was that HN019 bacterial
extract produced a delayed increase in the tension of
synchronized contractions with concomitant inhibition
of non-synchronized proximal colon contractions. Thus,
contents from lysed B. lactis HN019 bacteria demonstrated
prokinetic activity by increasing contractile tension. These
findings provide important insights into the potential colonic
actions of B. lactis HN019 relevant to the treatment of
constipation.
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